Business Brief -- Genelabs Technologies Inc.:
   Quarterly Deficit Widened;
   Acquisition Charge Is Cited
For the year, the Redwood City, Calif., biopharmaceutical
concern had a loss of $1.40 a share, compared with a 1990
loss of $4.6 million, or 31 cents a share. Revenue fell to
$4.3 million from $8.9 million in 1990. The 1991 loss
included a $9.3 million noncash charge as a result of
Genelabs' acquisition of a new unit, American Biotech
Resources Inc., which had a loss of $2.1 million.